GlassScriptPhysician profile
Carlton W Thomas
NPI 1205881398
$6,124.54
in general payments reported to CMS, 2019-2025
26 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,047 · 2020: $363 · 2021: $854 · 2022: $1,026 · 2023: $707 · 2024: $996 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,835.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,483.23 | 2019-2025 | Rinvoq, Mavyret, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $546.72 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $457.16 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $420.51 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $364.85 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $318.15 | 2021-2023 | |
| Janssen Biotech, INC. | $254.91 | 2019-2024 | Simponi, Simponi Aria, Stelara |
| Intercept Pharmaceuticals, INC. | $252.38 | 2019-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $191.69 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $167.56 | 2024-2025 | Zenpep |
| Allergan, INC. | $167.23 | 2019 | |
| Madrigal Pharmaceuticals | $121.70 | 2024-2025 | Rezdiffra, Resmetirom |
| Antares Pharma, INC. | $46.22 | 2020-2021 | |
| Genzyme Corporation | $43.39 | 2025 | |
| Shionogi INC | $42.87 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $35.02 | 2021 | |
| Merck Sharp & Dohme LLC | $34.96 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $30.53 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $26.40 | 2019-2021 | |
| Medtronic, INC. | $26.27 | 2024 | Gi Genius |
| Daiichi Sankyo INC. | $22.69 | 2022 | |
| Redhill Biopharma INC. | $21.99 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.08 | 2021 | |
| Ardelyx, INC. | $15.33 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $12.70 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlton Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.